Industries > Pharma > Diabetic Neuropathy Treatment: World Market 2018-2028
Diabetic Neuropathy Treatment: World Market 2018-2028
Analysis and Forecasts by Disorder (Peripheral, Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 215-page report you will receive 85 tables and 90 figures– all unavailable elsewhere.
The 215-page report provides clear detailed insight into the Global Diabetic Neuropathy market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
Report Scope
• Global Diabetic Neuropathy Market forecasts from 2018-2028
• This report breaks down the revenue forecast of the Global Diabetic Neuropathy market into these leading segments:
• By Disorder:
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Focal Neuropathy
• By Treatment:
• Drugs
• Anti-Depressants
• Anti-Convulsant
• Radiotherapy
• Physiotherapy
• By End User:
• Hospitals
• Clinics
• Pharmacy
Each submarket is further divided by region: North America, South America, Europe, Asia-Pacific and RoW
• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: the US, Canada, Mexico
• South America: Brazil, Argentina, Paraguay, Bolivia, Rest of South America
• Europe: Germany, France, the UK, Spain, Italy, Russia, Rest of Europe
• Asia-Pacific: China, Japan, India, Australia, Thailand, Rest of Asia-Pacific
• Rest of the World: Middle East, Africa, Other Countries
• Our study provides a SWOT analysis and Porter’s Five Forces analysis of the Global Diabetic Neuropathy market
• This report discusses the leading companies in the Global Diabetic Neuropathy market
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Johnson & Johnson
• GlaxoSmithKline plc.
• Lupin Limited
• Glenmark Pharmaceuticals Limited
• Depomed, Inc.
• Astellas Pharma Inc.
• Pfizer Inc.
Visiongain’s study is intended for anyone requiring commercial analyses for the Global Diabetic Neuropathy Market. You find data, trends and predictions.
Buy our report today Diabetic Neuropathy Treatment: World Market 2018-2028: Analysis and Forecasts by Disorder (Peripheral, Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Global Diabetic Neuropathy Treatment Market Overview
1.2 Research Methodology
1.2.1 Primary Research
1.2.2 Secondary Research
1.2.3 Market Evaluation & Forecasting Methodology
1.3 Global Diabetic Neuropathy Treatment Market Segmentation
1.4 Overview of Findings
1.5 Why You Should Read This Report
1.6 How this report delivers?
1.7 Key Questions Answered by This Analytical Report
1.8 Frequently Asked Questions (FAQ)
1.9 Who is This Report For?
1.10 Associated Visiongain Reports
1.11 About Visiongain
2. Introduction to Diabetic Neuropathy Treatment Market
3. Global Diabetic Neuropathy Treatment Market Forecast to 2028
4. Global Diabetic Neuropathy Treatment Market, by Disorder: Market Forecast to 2028
4.1 Overview
4.2 Peripheral Neuropathy
4.3 Autonomic Neuropathy
4.4 Proximal Neuropathy
4.5 Focal Neuropathy
5. Global Diabetic Neuropathy Treatment Market by Treatment: Market Forecast to 2028
5.1 Overview
5.2 Drugs
5.3 Anti-depressants
5.4 Anti-convulsant
5.5 Radiotherapy
5.6 Physiotherapy
5.7 Others
6. Global Diabetic Neuropathy Treatment Market by End-User: Market Forecast to 2028
6.1 Overview
6.2 Hospitals
6.3 Clinics
6.4 Pharmacy
7. Regional Diabetic Neuropathy Treatment Market Forecasts to 2027
7.1 Regional Diabetic Neuropathy Treatment Market Forecast Overview
7.2 North American Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.2.1 USA Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.2.2 Canada Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.2.3 Mexico Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3 South American Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.1 Brazil Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.2 Argentina Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.3 Paraguay Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.4 Bolivia Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.3.5 Rest of South America Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4 European Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.1 France Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.2 Germany Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.3 UK Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.4 Spain Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.5 Italy Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.6 Russia Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.4.7 Rest of Europe Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5 Asia-Pacific Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.1 China Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.2 Japan Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.3 India Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.4 Australia Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.5 Thailand Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.5.6 Rest of Asia-Pacific Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.6 Rest of World Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.6.1 Middle East Diabetic Neuropathy Treatment Market Forecast 2017-2028
7.6.2 Africa Cancer Diabetic Neuropathy Treatment Forecast 2017-2028
7.6.3 Other Countries Diabetic Neuropathy Treatment Market Forecast 2017-2028
8. Diabetic Neuropathy Treatment Market, Qualitative Analysis, 2017-2028
8.1 Porter’s Five Forces Analysis of the Diabetic Neuropathy Treatment Market 2017-2028
8.1.1 Bargaining Power of Buyers (Medium)
8.1.2 Bargaining Power of Suppliers (Low)
8.1.3 Threat of New Entrants (Low)
8.1.4 Threat of Substitute Products (Low)
8.1.5 Intensity of Competitive Rivalry (High)
8.2 Drivers, Restrains & Opportunities
8.2.1 Drivers
8.2.1.1 Increasing Incidences Of Diabetes
8.2.1.2 Increasing Aging Population
8.2.2 Restraints
8.2.2.1 Stringent Government Regulation
8.2.3 Opportunities
8.2.3.1 Ongoing Research And Development Related To Diabetes Neuropathy
9. Leading Companies in Diabetic Neuropathy Treatment Market
9.1 GlaxoSmithKline PLC
9.1.1 GlaxoSmithKline PLC: Company Overview
9.1.2 GlaxoSmithKline PLC: Product Portfolio
9.2 F. Hoffmann-La Roche AG
9.2.1 F. Hoffmann-La Roche: Company Overview
9.2.2 F. Hoffmann-La Roche: Product Portfolio
9.2.3 F. Hoffmann-La Roche: Recent Developments
9.3 Pfizer Inc.
9.3.1 Pfizer Inc.: Company Overview
9.3.2 Pfizer Inc.: Product Portfolio
9.4 Abbott Diagnostics (A Business Division of Abbott Laboratories Inc.)
9.4.1 Abbott Diagnostics: Company Overview
9.4.2 Abbott Diagnostics: Product Portfolio
9.5 Johnson & Johnson
9.5.1 Johnson & Johnson: Company Overview
9.5.2 Johnson & Johnson: Product Portfolio
9.5.3 Johnson & Johnson: Recent Developments
9.6 Eli Lilly and Company
9.6.1 Eli Lilly and Company: Company Overview
9.6.2 Eli Lilly and Company: Product Portfolio
9.7 Astellas Pharma, Inc.
9.7.1 Astellas Pharma, Inc.: Company Overview
9.7.2 Astellas Pharma, Inc.: Recent Development
9.8 Glenmark Pharmaceuticals Ltd.
9.8.1 Glenmark Pharmaceuticals Ltd.: Company Overview
9.8.2 Glenmark Pharmaceuticals Ltd.: Product Portfolio
9.9 Depomed, Inc.
9.9.1 Depomed, Inc. : Company Overview
9.9.2 Depomed, Inc.: Recent Development
9.10 Lupin Ltd.
9.10.1 Lupin Ltd.: Company Overview
9.10.2 Lupin Ltd.: Product Portfolio
9.11 Other Companies Involved in Diabetic Neuropathy Treatment Market
10. Conclusions
10.1 Current Leading Segments
10.2 Leading Regional Markets
10.3 Emerging Markets
10.4 The Future of the Market?
11. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
List of Figures
Figure 1.1. Diabetic Neuropathy Treatment Market Segmentation
Figure 3.1 Diabetic Neuropathy Treatment, by Disorder, ($bn), 2017-2028
Figure 3.2 Global Diabetic Neuropathy Treatment Market, by Treatment, ($bn), 2017-2028
Figure 3.3 Global Diabetic Neuropathy Treatment Market, by End-User, ($bn), 2017-2028
Figure 4.1 Global Diabetic Neuropathy Treatment Market Forecast, by Disorder ($bn) 2017-2028
Figure 4.2 Diabetic Neuropathy Treatment Market, by Disorder, Market Share (%), 2017
Figure 4.3 Global Diabetic Neuropathy Treatment Market Forecast for Peripheral Neuropathy, by Geography, ($bn) 2017-2028
Figure 4.4 Global Diabetic Neuropathy Treatment Market Forecast for Autonomic Neuropathy, by Geography, ($bn) 2017-2028
Figure 4.5 Global Diabetic Neuropathy Treatment Market Forecast for Proximal Neuropathy, by Geography, ($bn) 2017-2028
Figure 4.6 Global Diabetic Neuropathy Treatment Market Forecast for Focal Neuropathy, by Geography, ($bn) 2017-2028
Figure 5.1 Global Neuropathy Treatment Market Forecast for Treatment, by Treatment ($bn) 2017-2028
Figure 5.2 Global Diabetic Neuropathy Treatment Market, by Treatment, Market Share (%), 2017
Figure 5.3 Global Diabetic Neuropathy Treatment Market for Drugs Forecast, by Geography($bn) 2017-2028
Figure 5.4 Global Diabetic Neuropathy Treatment Market for Anti-depressants Forecast, by Geography($bn) 2017-2028
Figure 5.5 Global Diabetic Neuropathy Treatment Market for Anti-convulsant Forecast, by Geography($bn) 2017-2028
Figure 5.6 Global Diabetic Neuropathy Treatment Market for Radiotherapy Forecast, by Geography($bn) 2017-2028
Figure 5.7 Global Diabetic Neuropathy Treatment Market for Physiotherapy Forecast, by Geography($bn) 2017-2028
Figure 5.8 Global Diabetic Neuropathy Treatment Market for Other Immunotherapeutic Agents Forecast, by Geography($bn) 2017-2028
Figure 6.1 Global Neuropathy Treatment Market Forecast for Treatment, by End-User ($bn) 2017-2028
Figure 6.2 Global Diabetic Neuropathy Treatment Market, by End-User, Market Share (%), 2017
Figure 6.3 Global Diabetic Neuropathy Treatment Market for Hospitals Forecast, by Geography($bn) 2017-2028
Figure 6.4 Global Diabetic Neuropathy Treatment Market for Clinics Forecast, by Geography ($bn) 2017-2028
Figure 6.5 Global Diabetic Neuropathy Treatment Market for Pharmacy Forecast, by Geography($bn) 2017-2028
Figure 7.1 Global Diabetic Neuropathy Treatment Market Forecast, by Geography, by Geography($bn) 2017-2028
Figure 7.2 Global Diabetic Neuropathy Treatment Market Forecast, by Geography, Market Share (%), 2017
Figure 7.3 North America Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.4 North America Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.5 USA Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.6 Canada Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.7 Mexico Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.8 South America Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.9 South America Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.10 Brazil Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.11 Argentina Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.12 Paraguay Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.13 Bolivia Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.14 Rest of South America Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.15 Europe Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.16 Europe Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.17 France Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.18 Germany Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.19 UK Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.20 Spain Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.21 Italy Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.22 Russia Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.23 Rest of Europe Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.24 Asia-Pacific Diabetic Neuropathy Treatment Market Forecast, by Country ($bn) 2017-2028
Figure 7.25 Asia-Pacific Diabetic Neuropathy Treatment Market, Market Share (%), 2017
Figure 7.26 China Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.27 Japan Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.28 India Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.29 Australia Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.30 Thailand Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.31 Rest of Asia-Pacific Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.32 RoW Diabetic Neuropathy Treatment Market Forecast, by Country($bn) 2017-2028
Figure 7.33 Rest of World Diabetic Neuropathy Treatment Market, by Country, Market Share (%), 2017
Figure 7.34 Middle East Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.35 Africa Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 7.36 Other Countries Diabetic Neuropathy Treatment Market Forecast ($bn) 2017-2028
Figure 8.1 Porter’s Five Forces Analysis of the Diabetic Neuropathy Treatment Market
Figure 8.2 Estimated of person aged 60 years and over in year 2015, 2030 and 2050
Figure 9.1 GlaxoSmithKline PLC, Revenue, ($million), 2012-2016
Figure 9.2 GlaxoSmithKline PLC, Product Segments Share (%), 2016
Figure 9.3 GlaxoSmithKline PLC, Geographical Presence Share (%), 2016
Figure 9.4 F. Hoffmann-La Roche, Revenue, ($million), 2012-2016
Figure 9.5 F. Hoffmann-La Roche, Product Segments Share (%), 2016
Figure 9.6 F. Hoffmann-La Roche, Geographical Presence Share (%), 2016
Figure 9.7 Pfizer Inc., Revenue, ($million), 2012-2016
Figure 9.8 Pfizer Inc., Product Segments Share (%), 2016
Figure 9.9 Pfizer Inc., Geographical Presence Share (%), 2016
Figure 9.10 Abbott Diagnostics , Revenue, ($million), 2012-2016
Figure 9.11 Abbott Diagnostics (Segment) , Revenue, ($million), 2012-2016
Figure 9.12 Abbott Diagnostics, Product Segments Share (%), 2016
Figure 9.13 Abbott Diagnostics, Geographic Presence Share (%), 2016
Figure 9.14 Johnson & Johnson, Revenue, ($million), 2012-2016
Figure 9.15 Johnson & Johnson, Product Segments Share (%), 2016
Figure 9.16 Johnson & Johnson, Geographical Presence Share (%), 2016
Figure 9.17 Eli Lilly and Company, Revenue, ($million), 2012-2016
Figure 9.18 Eli Lilly and Company, Product Segments Share (%), 2016
Figure 9.19 Eli Lilly and Company, Geographical Presence Share (%), 2016
Figure 9.20 Astellas Pharma, Inc., Revenue, ($million), 2013-2017
Figure 9.21 Astellas Pharma, Inc., Geographical Presence Share (%), 2017
Figure 9.22 Glenmark Pharmaceuticals Ltd., Revenue, ($million), 2013-2017
Figure 9.23 Depomed, Inc., Revenue, ($million), 2012-2016
Figure 9.24 Lupin Ltd., Revenue, ($million), 2013-2017
Figure 9.25 Lupin, Ltd., Geographical Presence Share (%), 2017
Figure 10.1 World Diabetic Neuropathy Treatment, by Disorder, ($bn), 2017-2028
Figure 10.2 World Diabetic Neuropathy Treatment, by Treatment, ($bn), 2017-2028
Figure 10.3 World Diabetic Neuropathy Treatment, by End-User, ($bn), 2017-2028
Figure 10.4. World Diabetic Neuropathy Treatment, by Geography, ($bn), 2017-2028
List of Tables
Table 3.1 Table 3.1 Global Diabetic Neuropathy Treatment Market Forecast ($bn, AGR%, CAGR%) 2017-2028
Table 4.1 Diabetic Neuropathy Treatment Market, by Disorder, Forecast ($bn, AGR%, CAGR%) 2017-2028
Table 4.2 Global Diabetic Neuropathy Treatment Market Forecast for Peripheral Neuropathy, ($bn, AGR%, CAGR%) 2017-2028
Table 4.3 Global Diabetic Neuropathy Treatment Market Forecast for Peripheral Neuropathy, by Geography, ($bn, AGR%, CAGR%) 2017-2028
Table 4.4 Global Diabetic Neuropathy Treatment Market Forecast for Autonomic Neuropathy, ($bn, AGR%, CAGR%) 2017-2028
Table 4.5 Global Diabetic Neuropathy Treatment Market Forecast for Autonomic Neuropathy, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 4.6 Global Diabetic Neuropathy Treatment Market Forecast for Proximal Neuropathy, ($bn, AGR%, CAGR%) 2017-2028
Table 4.7 Global Diabetic Neuropathy Treatment Market Forecast for Proximal Neuropathy, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 4.8 Global Diabetic Neuropathy Treatment Market Forecast for Focal Neuropathy, ($bn, AGR%, CAGR%) 2017-2028
Table 4.9 Global Diabetic Neuropathy Treatment Market Forecast for Focal Neuropathy, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.1 Global Diabetic Neuropathy Treatment Market, by Treatment ($bn, AGR%, CAGR%) 2017-2028
Table 5.2 Global Diabetic Neuropathy Treatment Market for Drugs, ($bn, AGR%, CAGR%) 2017-2028
Table 5.3 Global Diabetic Neuropathy Treatment Market for Drugs, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.4 Global Diabetic Neuropathy Treatment Market for Anti-depressants ($bn, AGR%, CAGR%) 2017-2028
Table 5.5 Global Diabetic Neuropathy Treatment Market for Anti-depressants, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.6 Global Diabetic Neuropathy Treatment Market for Anti-convulsant ($bn, AGR%, CAGR%) 2017-2028
Table 5.7 Global Diabetic Neuropathy Treatment Market for Anti-convulsant, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.8 Global Diabetic Neuropathy Treatment Market for Radiotherapy Concentrates ($bn, AGR%, CAGR%) 2017-2028
Table 5.9 Global Diabetic Neuropathy Treatment Market for Radiotherapy by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.10 Diabetic Neuropathy Treatment Market for Physiotherapy ($bn, AGR%, CAGR%) 2017-2028
Table 5.11 Global Diabetic Neuropathy Treatment Market for Physiotherapy, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 5.12 Global Diabetic Neuropathy Treatment Market for Other Immunotherapeutic Agents ($bn, AGR%, CAGR%) 2017-2028
Table 5.13 Global Diabetic Neuropathy Treatment Market for Other Immunotherapeutic Agents, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 6.1 Global Diabetic Neuropathy Treatment Market, by End-User ($bn, AGR%, CAGR%) 2017-2028
Table 6.2 Global Diabetic Neuropathy Treatment Market for Hospitals, ($bn, AGR%, CAGR%) 2017-2028
Table 6.3 Global Diabetic Neuropathy Treatment Market for Hospitals, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 6.4 Global Diabetic Neuropathy Treatment Market for Clinics ($bn, AGR%, CAGR%) 2017-2028
Table 6.5 Global Diabetic Neuropathy Treatment Market for Clinics by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 6.6 Global Diabetic Neuropathy Treatment Market for Pharmacy ($bn, AGR%, CAGR%) 2017-2028
Table 6.7 Global Diabetic Neuropathy Treatment Market for Pharmacy, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 7.1 Global Diabetic Neuropathy Treatment Market Forecast, by Geography ($bn, AGR%, CAGR%) 2017-2028
Table 7.2 North America Diabetic Neuropathy Treatment Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.3 USA Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.4 Canada Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.5 Mexico Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.6 South America Diabetic Neuropathy Treatment Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.7 Brazil Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.8 Argentina Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.9 Paraguay Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.10 Bolivia Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.11 Rest of South America Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.12 European Diabetic Neuropathy Treatment Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.13. France Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.14 Germany Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.15 UK Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.16 Spain Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.17 Italy Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.18 Russia Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.19 Rest of European Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.20 Asia-Pacific Diabetic Neuropathy Treatment Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.21 China Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.22 Japan Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.23 India Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.24 Australia Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.25 Thailand Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.26 Rest of Asia-Pacific Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.27 Rest of World Diabetic Neuropathy Treatment Market Forecast, by Country ($bn, AGR%, CAGR%) 2017-2028
Table 7.28 Middle East Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.29 Africa Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 7.30 Other Countries Diabetic Neuropathy Treatment Market Forecast, ($bn, AGR%, CAGR%) 2017-2028
Table 9.1 GlaxoSmithKline PLC: Company Overview
Table 9.2 GlaxoSmithKline PLC: Product Portfolio
Table 9.3 F. Hoffmann-La Roche : Company Overview
Table 9.4 F. Hoffmann-La Roche : Product Portfolio
Table 9.5 F. Hoffmann-La Roche : Recent Developments
Table 9.6 Pfizer Inc.: Company Overview
Table 9.7 Pfizer Inc.: Product Portfolio
Table 9.8 Abbott Diagnostics: Company Overview
Table 9.9 Abbott Diagnostics: Product Portfolio
Table 9.10 Johnson & Johnson: Company Overview
Table 9.11 Johnson & Johnson: Product Portfolio
Table 9.12 Johnson & Johnson: Recent Developments
Table 9.13 Eli Lilly and Company: Company Overview
Table 9.14 Eli Lilly and Company: Product Portfolio
Table 9.15 Astellas Pharma, Inc.: Company Overview
Table 9.16 Astellas Pharma, Inc.: Recent Developments
Table 9.17 Glenmark Pharmaceuticals Ltd.: Company Overview
Table 9.18 Glenmark Pharmaceuticals Ltd.: Product Portfolio
Table 9.20 Depomed, Inc.: Company Overview
Table 9.21 Depomed, Inc.: Recent Developments
Table 9.22 Lupin Ltd.: Company Overview
Table 9.23 Lupin Ltd.: Product Portfolio
Table 9.24 Other Companies for Diabetic Neuropathy Treatment Market
Table 9.24 Other Companies for Diabetic Neuropathy Treatment Market
Table 9.24 Other Companies for Diabetic Neuropathy Treatment Market
Abbott Laboratories
AbbVie, Inc.
Alkermes Plc
Amarin Corp. Plc
Amgen, Inc.
Amnis Corporation
Array BioPharma, Inc.
Associates Of Cape Cod Inc.
Astex Pharmaceuticals Inc.
AstraZeneca Plc
ASYMPTOTE LTD
Atom Medical Corporation
Bayer AG
Bayer Corporation
Bayer HealthCare AG
Bayer Schering Pharma Aktiengesellschaft
BioLife Solutions, Inc.
BioMarin Pharmaceutical, Inc.
Biotest AG
Bristol-Myers Squibb Co.
Cardax, Inc.
Cardinal Health, Inc.
Ceapro, Inc.
Celgene Corp.
Cephalon, Inc.
Chugai Pharmaceutical Co., Ltd.
CK Life Sciences International (Holdings), Inc.
Consensys Imaging Service Inc.
Cornerstone Research & Development Inc.
Crescendo Bioscience, Inc.
CTI BioPharma Corp.
Deroyal Industries Inc.
Domain Therapeutics SA
Emd Millipore Corporation
Emd Serono Inc.
Endo International Plc
European Medicines Agency
Evotec AG
Galderma Sa
GE HEALTHCARE LTD
GlaxoSmithKline Plc
Henry Schein, Inc.
Herbert Waldmann GmbH & Co. KG
Illumina, Inc.
Institut Bergonie
Janssen Biotech, Inc.
JHL Biotech, Inc.
Johnson & Johnson
Laboratoire Theramex
Laboratory Corp. of America Holdings
LifeWatch AG
Lombard Medical, Inc.
Lonza Group AG
McKesson Corp.
Medline Industries Inc.
Medtronic Plc
Merck KGaA
MorphoSys AG
Motion Picture And Television Fund
Myrexis, Inc.
Myriad Genetics, Inc.
National Biological Corp.
National Cancer Institute
Natus Medical Incorporated
NBTY, Inc.
Neptune Technologies & Bioresources, Inc.
Nexvet Biopharma PLC
nice Neotech Medical Systems Pvt. Ltd.
Northwell Health Inc.
Novartis AG
OpenLink Financial LLC
Opexa Therapeutics, Inc.
Otsuka Pharmaceutical Co. Ltd.
Owens & Minor, Inc.
Panacos Pharmaceuticals, Inc.
PELICAN HEALTHCARE LTD
Pfizer Inc.
Pharma Mar SA
Phillips
Phoenix Medical Systems Pvt. Ltd.
Polymer Technology Systems Inc.
Progyny Inc.
Quanterix Corp.
Quest Diagnostics, Inc.
Smith & Nephew Plc
Spectrum Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc.
Windtree Therapeutics, Inc.
List of Organizations
China Food and Drug Administration (CFDA)
European Medicines Agency (EMA)
Food and Drug Administration (FDA) [US]
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
Ministry of Health, Labor and Welfare (MHLW) [Japan]
National Health Service (NHS) [UK]
World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Diabetic Neuropathy Treatment: World Market 2018-2028Download sample pages
Complete the form below to download your free sample pages for Diabetic Neuropathy Treatment: World Market 2018-2028Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033
23 May 2023
